JNCI-Journal of the National Cancer Institute-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2244552, encodeId=6f3a224455268, content=没外审就review complete是啥意思，也不作出决定, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0f86442273, createdName=ms4000000681775086, createdTime=Mon Dec 23 20:55:52 CST 2024, time=2024-12-23, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=1079952, encodeId=92e010e995260, content=很快变成review complete 是不是秒拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEKtz8V7A0HhUFibPwRaIGuVmkOabRMZMFdRzw39RErlwqwxiciatOSOF6EKvqzCXFYU9BfOU8wA9KAWg/0, createdBy=32b61932414, createdName=OceanSL, createdTime=Tue Dec 14 14:58:43 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=564430, encodeId=5e72564430bc, content=Submission Technical Check Started状态持续了快半个月了，是不是放假了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=380, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26b81522186, createdName=jfazj, createdTime=Fri Dec 14 11:44:00 CST 2018, time=2018-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2155971, encodeId=de6721559e1b7, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：很好的期刊，只是这些年有点落寞了，不好中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/iaqwic5175nrsPthItiav2krgITEeMQ2icKV217mmNAw5IbUf9IZhxfJ4qIfOo59YMibg9n6KuicjX6wFCibesxO8bpOtCb4DsFbp41/0, createdBy=1a8e2047779, createdName=ms9508293866653270, createdTime=Mon Sep 04 08:27:39 CST 2023, time=2023-09-04, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2149454, encodeId=6c10214945484, content=偏重的研究方向：肿瘤 经验分享：投稿后，under consideration4周了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57818111868, createdName=ms6000001984003159, createdTime=Sun Jul 23 16:52:24 CST 2023, time=2023-07-23, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2150540, encodeId=ccec215054061, content=投稿命中率:25.0 偏重的研究方向：甲状腺肿瘤 经验分享：Submission Technical Check Started：一周 Under consideration：一周 rejected, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8336506161, createdName=ms2000000185262432, createdTime=Sun Jul 30 20:18:55 CST 2023, time=2023-07-30, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=600522, encodeId=384d600522d2, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤免疫 经验分享：1月23日过年之前投一篇article，3月3日审稿回来大修。三个审稿人一个没意见，另外俩一共提了9个意见，都还比较到要害，可见审稿人水平很高。一个月时间修改后发回，5月初被接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=312, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ec85338815, createdName=ms6000001848255584, createdTime=Mon May 25 19:43:18 CST 2020, time=2020-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2098657, encodeId=a42d209865e47, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;Cancer 经验分享：杂志主要接收临床相关的文章，观点新颖，提出新的肿瘤治疗方案，并用详细严谨的临床数据作支撑。15年以后比较少接收基础类的文章，还是挺不错的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sat Nov 05 09:22:52 CST 2022, time=2022-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553812, encodeId=a27b5538126a, content=博士.结果怎么样?jfazj 2017-10-17 发表:: 研究方向:radiotherapy;; 接收率:约5% 审稿时间:约2个月 SCI(2016):12.589 SCI(2015):11.37 SCI(2014):12.583 mark一下.投稿42天.希望10月底能收到 decision letter! 希望有个好结果!jfazj 2017-10-17 11:09:00 发表: mark一下.投稿42天.希望10月底能收到 decision letter! 希望有个好结果!, beContent=jfazj 2017-10-17 发表:: 研究方向:radiotherapy;; 接收率:约5% 审稿时间:约2个月 SCI(2016):12.589 SCI(2015):11.37 SCI(2014):12.583 mark一下.投稿42天.希望10月底能收到 decision letter! 希望有个好结果!, objectType=tool_impact_factor, channel=null, level=null, likeNumber=418, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170224/IMG58AFD85BAD0444153.jpg, createdBy=25412017681, createdName=Dr. H, createdTime=Sat Mar 17 00:00:00 CST 2018, time=2018-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093753, encodeId=894b1093e5346, content=常见的SCI文章类型有哪些？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=176, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=)]

2024-12-23 ms4000000681775086 来自福建省

没外审就review complete是啥意思，也不作出决定

8 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2244552, encodeId=6f3a224455268, content=没外审就review complete是啥意思，也不作出决定, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0f86442273, createdName=ms4000000681775086, createdTime=Mon Dec 23 20:55:52 CST 2024, time=2024-12-23, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=1079952, encodeId=92e010e995260, content=很快变成review complete 是不是秒拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEKtz8V7A0HhUFibPwRaIGuVmkOabRMZMFdRzw39RErlwqwxiciatOSOF6EKvqzCXFYU9BfOU8wA9KAWg/0, createdBy=32b61932414, createdName=OceanSL, createdTime=Tue Dec 14 14:58:43 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=564430, encodeId=5e72564430bc, content=Submission Technical Check Started状态持续了快半个月了，是不是放假了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=380, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26b81522186, createdName=jfazj, createdTime=Fri Dec 14 11:44:00 CST 2018, time=2018-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2155971, encodeId=de6721559e1b7, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：很好的期刊，只是这些年有点落寞了，不好中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/iaqwic5175nrsPthItiav2krgITEeMQ2icKV217mmNAw5IbUf9IZhxfJ4qIfOo59YMibg9n6KuicjX6wFCibesxO8bpOtCb4DsFbp41/0, createdBy=1a8e2047779, createdName=ms9508293866653270, createdTime=Mon Sep 04 08:27:39 CST 2023, time=2023-09-04, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2149454, encodeId=6c10214945484, content=偏重的研究方向：肿瘤 经验分享：投稿后，under consideration4周了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57818111868, createdName=ms6000001984003159, createdTime=Sun Jul 23 16:52:24 CST 2023, time=2023-07-23, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2150540, encodeId=ccec215054061, content=投稿命中率:25.0 偏重的研究方向：甲状腺肿瘤 经验分享：Submission Technical Check Started：一周 Under consideration：一周 rejected, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8336506161, createdName=ms2000000185262432, createdTime=Sun Jul 30 20:18:55 CST 2023, time=2023-07-30, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=600522, encodeId=384d600522d2, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤免疫 经验分享：1月23日过年之前投一篇article，3月3日审稿回来大修。三个审稿人一个没意见，另外俩一共提了9个意见，都还比较到要害，可见审稿人水平很高。一个月时间修改后发回，5月初被接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=312, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ec85338815, createdName=ms6000001848255584, createdTime=Mon May 25 19:43:18 CST 2020, time=2020-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2098657, encodeId=a42d209865e47, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;Cancer 经验分享：杂志主要接收临床相关的文章，观点新颖，提出新的肿瘤治疗方案，并用详细严谨的临床数据作支撑。15年以后比较少接收基础类的文章，还是挺不错的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sat Nov 05 09:22:52 CST 2022, time=2022-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553812, encodeId=a27b5538126a, content=博士.结果怎么样?jfazj 2017-10-17 发表:: 研究方向:radiotherapy;; 接收率:约5% 审稿时间:约2个月 SCI(2016):12.589 SCI(2015):11.37 SCI(2014):12.583 mark一下.投稿42天.希望10月底能收到 decision letter! 希望有个好结果!jfazj 2017-10-17 11:09:00 发表: mark一下.投稿42天.希望10月底能收到 decision letter! 希望有个好结果!, beContent=jfazj 2017-10-17 发表:: 研究方向:radiotherapy;; 接收率:约5% 审稿时间:约2个月 SCI(2016):12.589 SCI(2015):11.37 SCI(2014):12.583 mark一下.投稿42天.希望10月底能收到 decision letter! 希望有个好结果!, objectType=tool_impact_factor, channel=null, level=null, likeNumber=418, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170224/IMG58AFD85BAD0444153.jpg, createdBy=25412017681, createdName=Dr. H, createdTime=Sat Mar 17 00:00:00 CST 2018, time=2018-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093753, encodeId=894b1093e5346, content=常见的SCI文章类型有哪些？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=176, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=)]

2021-12-14 OceanSL

很快变成review complete 是不是秒拒

156 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2244552, encodeId=6f3a224455268, content=没外审就review complete是啥意思，也不作出决定, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0f86442273, createdName=ms4000000681775086, createdTime=Mon Dec 23 20:55:52 CST 2024, time=2024-12-23, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=1079952, encodeId=92e010e995260, content=很快变成review complete 是不是秒拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEKtz8V7A0HhUFibPwRaIGuVmkOabRMZMFdRzw39RErlwqwxiciatOSOF6EKvqzCXFYU9BfOU8wA9KAWg/0, createdBy=32b61932414, createdName=OceanSL, createdTime=Tue Dec 14 14:58:43 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=564430, encodeId=5e72564430bc, content=Submission Technical Check Started状态持续了快半个月了，是不是放假了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=380, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26b81522186, createdName=jfazj, createdTime=Fri Dec 14 11:44:00 CST 2018, time=2018-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2155971, encodeId=de6721559e1b7, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：很好的期刊，只是这些年有点落寞了，不好中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/iaqwic5175nrsPthItiav2krgITEeMQ2icKV217mmNAw5IbUf9IZhxfJ4qIfOo59YMibg9n6KuicjX6wFCibesxO8bpOtCb4DsFbp41/0, createdBy=1a8e2047779, createdName=ms9508293866653270, createdTime=Mon Sep 04 08:27:39 CST 2023, time=2023-09-04, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2149454, encodeId=6c10214945484, content=偏重的研究方向：肿瘤 经验分享：投稿后，under consideration4周了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57818111868, createdName=ms6000001984003159, createdTime=Sun Jul 23 16:52:24 CST 2023, time=2023-07-23, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2150540, encodeId=ccec215054061, content=投稿命中率:25.0 偏重的研究方向：甲状腺肿瘤 经验分享：Submission Technical Check Started：一周 Under consideration：一周 rejected, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8336506161, createdName=ms2000000185262432, createdTime=Sun Jul 30 20:18:55 CST 2023, time=2023-07-30, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=600522, encodeId=384d600522d2, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤免疫 经验分享：1月23日过年之前投一篇article，3月3日审稿回来大修。三个审稿人一个没意见，另外俩一共提了9个意见，都还比较到要害，可见审稿人水平很高。一个月时间修改后发回，5月初被接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=312, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ec85338815, createdName=ms6000001848255584, createdTime=Mon May 25 19:43:18 CST 2020, time=2020-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2098657, encodeId=a42d209865e47, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;Cancer 经验分享：杂志主要接收临床相关的文章，观点新颖，提出新的肿瘤治疗方案，并用详细严谨的临床数据作支撑。15年以后比较少接收基础类的文章，还是挺不错的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sat Nov 05 09:22:52 CST 2022, time=2022-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553812, encodeId=a27b5538126a, content=博士.结果怎么样?jfazj 2017-10-17 发表:: 研究方向:radiotherapy;; 接收率:约5% 审稿时间:约2个月 SCI(2016):12.589 SCI(2015):11.37 SCI(2014):12.583 mark一下.投稿42天.希望10月底能收到 decision letter! 希望有个好结果!jfazj 2017-10-17 11:09:00 发表: mark一下.投稿42天.希望10月底能收到 decision letter! 希望有个好结果!, beContent=jfazj 2017-10-17 发表:: 研究方向:radiotherapy;; 接收率:约5% 审稿时间:约2个月 SCI(2016):12.589 SCI(2015):11.37 SCI(2014):12.583 mark一下.投稿42天.希望10月底能收到 decision letter! 希望有个好结果!, objectType=tool_impact_factor, channel=null, level=null, likeNumber=418, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170224/IMG58AFD85BAD0444153.jpg, createdBy=25412017681, createdName=Dr. H, createdTime=Sat Mar 17 00:00:00 CST 2018, time=2018-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093753, encodeId=894b1093e5346, content=常见的SCI文章类型有哪些？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=176, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=)]

2018-12-14 jfazj

Submission Technical Check Started状态持续了快半个月了，是不是放假了？

380 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2244552, encodeId=6f3a224455268, content=没外审就review complete是啥意思，也不作出决定, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0f86442273, createdName=ms4000000681775086, createdTime=Mon Dec 23 20:55:52 CST 2024, time=2024-12-23, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=1079952, encodeId=92e010e995260, content=很快变成review complete 是不是秒拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEKtz8V7A0HhUFibPwRaIGuVmkOabRMZMFdRzw39RErlwqwxiciatOSOF6EKvqzCXFYU9BfOU8wA9KAWg/0, createdBy=32b61932414, createdName=OceanSL, createdTime=Tue Dec 14 14:58:43 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=564430, encodeId=5e72564430bc, content=Submission Technical Check Started状态持续了快半个月了，是不是放假了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=380, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26b81522186, createdName=jfazj, createdTime=Fri Dec 14 11:44:00 CST 2018, time=2018-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2155971, encodeId=de6721559e1b7, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：很好的期刊，只是这些年有点落寞了，不好中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/iaqwic5175nrsPthItiav2krgITEeMQ2icKV217mmNAw5IbUf9IZhxfJ4qIfOo59YMibg9n6KuicjX6wFCibesxO8bpOtCb4DsFbp41/0, createdBy=1a8e2047779, createdName=ms9508293866653270, createdTime=Mon Sep 04 08:27:39 CST 2023, time=2023-09-04, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2149454, encodeId=6c10214945484, content=偏重的研究方向：肿瘤 经验分享：投稿后，under consideration4周了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57818111868, createdName=ms6000001984003159, createdTime=Sun Jul 23 16:52:24 CST 2023, time=2023-07-23, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2150540, encodeId=ccec215054061, content=投稿命中率:25.0 偏重的研究方向：甲状腺肿瘤 经验分享：Submission Technical Check Started：一周 Under consideration：一周 rejected, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8336506161, createdName=ms2000000185262432, createdTime=Sun Jul 30 20:18:55 CST 2023, time=2023-07-30, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=600522, encodeId=384d600522d2, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤免疫 经验分享：1月23日过年之前投一篇article，3月3日审稿回来大修。三个审稿人一个没意见，另外俩一共提了9个意见，都还比较到要害，可见审稿人水平很高。一个月时间修改后发回，5月初被接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=312, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ec85338815, createdName=ms6000001848255584, createdTime=Mon May 25 19:43:18 CST 2020, time=2020-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2098657, encodeId=a42d209865e47, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;Cancer 经验分享：杂志主要接收临床相关的文章，观点新颖，提出新的肿瘤治疗方案，并用详细严谨的临床数据作支撑。15年以后比较少接收基础类的文章，还是挺不错的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sat Nov 05 09:22:52 CST 2022, time=2022-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553812, encodeId=a27b5538126a, content=博士.结果怎么样?jfazj 2017-10-17 发表:: 研究方向:radiotherapy;; 接收率:约5% 审稿时间:约2个月 SCI(2016):12.589 SCI(2015):11.37 SCI(2014):12.583 mark一下.投稿42天.希望10月底能收到 decision letter! 希望有个好结果!jfazj 2017-10-17 11:09:00 发表: mark一下.投稿42天.希望10月底能收到 decision letter! 希望有个好结果!, beContent=jfazj 2017-10-17 发表:: 研究方向:radiotherapy;; 接收率:约5% 审稿时间:约2个月 SCI(2016):12.589 SCI(2015):11.37 SCI(2014):12.583 mark一下.投稿42天.希望10月底能收到 decision letter! 希望有个好结果!, objectType=tool_impact_factor, channel=null, level=null, likeNumber=418, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170224/IMG58AFD85BAD0444153.jpg, createdBy=25412017681, createdName=Dr. H, createdTime=Sat Mar 17 00:00:00 CST 2018, time=2018-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093753, encodeId=894b1093e5346, content=常见的SCI文章类型有哪些？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=176, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=)]

2023-09-04 ms9508293866653270 来自陕西省

审稿速度:3.0 | 投稿命中率:25.0
经验分享：很好的期刊，只是这些年有点落寞了，不好中

113 0

[GetPortalCommentsPageByObjectIdResponse(id=2244552, encodeId=6f3a224455268, content=没外审就review complete是啥意思，也不作出决定, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0f86442273, createdName=ms4000000681775086, createdTime=Mon Dec 23 20:55:52 CST 2024, time=2024-12-23, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=1079952, encodeId=92e010e995260, content=很快变成review complete 是不是秒拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEKtz8V7A0HhUFibPwRaIGuVmkOabRMZMFdRzw39RErlwqwxiciatOSOF6EKvqzCXFYU9BfOU8wA9KAWg/0, createdBy=32b61932414, createdName=OceanSL, createdTime=Tue Dec 14 14:58:43 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=564430, encodeId=5e72564430bc, content=Submission Technical Check Started状态持续了快半个月了，是不是放假了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=380, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26b81522186, createdName=jfazj, createdTime=Fri Dec 14 11:44:00 CST 2018, time=2018-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2155971, encodeId=de6721559e1b7, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：很好的期刊，只是这些年有点落寞了，不好中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/iaqwic5175nrsPthItiav2krgITEeMQ2icKV217mmNAw5IbUf9IZhxfJ4qIfOo59YMibg9n6KuicjX6wFCibesxO8bpOtCb4DsFbp41/0, createdBy=1a8e2047779, createdName=ms9508293866653270, createdTime=Mon Sep 04 08:27:39 CST 2023, time=2023-09-04, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2149454, encodeId=6c10214945484, content=偏重的研究方向：肿瘤 经验分享：投稿后，under consideration4周了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57818111868, createdName=ms6000001984003159, createdTime=Sun Jul 23 16:52:24 CST 2023, time=2023-07-23, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2150540, encodeId=ccec215054061, content=投稿命中率:25.0 偏重的研究方向：甲状腺肿瘤 经验分享：Submission Technical Check Started：一周 Under consideration：一周 rejected, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8336506161, createdName=ms2000000185262432, createdTime=Sun Jul 30 20:18:55 CST 2023, time=2023-07-30, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=600522, encodeId=384d600522d2, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤免疫 经验分享：1月23日过年之前投一篇article，3月3日审稿回来大修。三个审稿人一个没意见，另外俩一共提了9个意见，都还比较到要害，可见审稿人水平很高。一个月时间修改后发回，5月初被接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=312, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ec85338815, createdName=ms6000001848255584, createdTime=Mon May 25 19:43:18 CST 2020, time=2020-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2098657, encodeId=a42d209865e47, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;Cancer 经验分享：杂志主要接收临床相关的文章，观点新颖，提出新的肿瘤治疗方案，并用详细严谨的临床数据作支撑。15年以后比较少接收基础类的文章，还是挺不错的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sat Nov 05 09:22:52 CST 2022, time=2022-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553812, encodeId=a27b5538126a, content=博士.结果怎么样?jfazj 2017-10-17 发表:: 研究方向:radiotherapy;; 接收率:约5% 审稿时间:约2个月 SCI(2016):12.589 SCI(2015):11.37 SCI(2014):12.583 mark一下.投稿42天.希望10月底能收到 decision letter! 希望有个好结果!jfazj 2017-10-17 11:09:00 发表: mark一下.投稿42天.希望10月底能收到 decision letter! 希望有个好结果!, beContent=jfazj 2017-10-17 发表:: 研究方向:radiotherapy;; 接收率:约5% 审稿时间:约2个月 SCI(2016):12.589 SCI(2015):11.37 SCI(2014):12.583 mark一下.投稿42天.希望10月底能收到 decision letter! 希望有个好结果!, objectType=tool_impact_factor, channel=null, level=null, likeNumber=418, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170224/IMG58AFD85BAD0444153.jpg, createdBy=25412017681, createdName=Dr. H, createdTime=Sat Mar 17 00:00:00 CST 2018, time=2018-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093753, encodeId=894b1093e5346, content=常见的SCI文章类型有哪些？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=176, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=)]

2023-07-23 ms6000001984003159 来自广东省

偏重的研究方向：肿瘤
经验分享：投稿后，under consideration4周了

129 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=2244552, encodeId=6f3a224455268, content=没外审就review complete是啥意思，也不作出决定, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0f86442273, createdName=ms4000000681775086, createdTime=Mon Dec 23 20:55:52 CST 2024, time=2024-12-23, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=1079952, encodeId=92e010e995260, content=很快变成review complete 是不是秒拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEKtz8V7A0HhUFibPwRaIGuVmkOabRMZMFdRzw39RErlwqwxiciatOSOF6EKvqzCXFYU9BfOU8wA9KAWg/0, createdBy=32b61932414, createdName=OceanSL, createdTime=Tue Dec 14 14:58:43 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=564430, encodeId=5e72564430bc, content=Submission Technical Check Started状态持续了快半个月了，是不是放假了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=380, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26b81522186, createdName=jfazj, createdTime=Fri Dec 14 11:44:00 CST 2018, time=2018-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2155971, encodeId=de6721559e1b7, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：很好的期刊，只是这些年有点落寞了，不好中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/iaqwic5175nrsPthItiav2krgITEeMQ2icKV217mmNAw5IbUf9IZhxfJ4qIfOo59YMibg9n6KuicjX6wFCibesxO8bpOtCb4DsFbp41/0, createdBy=1a8e2047779, createdName=ms9508293866653270, createdTime=Mon Sep 04 08:27:39 CST 2023, time=2023-09-04, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2149454, encodeId=6c10214945484, content=偏重的研究方向：肿瘤 经验分享：投稿后，under consideration4周了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57818111868, createdName=ms6000001984003159, createdTime=Sun Jul 23 16:52:24 CST 2023, time=2023-07-23, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2150540, encodeId=ccec215054061, content=投稿命中率:25.0 偏重的研究方向：甲状腺肿瘤 经验分享：Submission Technical Check Started：一周 Under consideration：一周 rejected, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8336506161, createdName=ms2000000185262432, createdTime=Sun Jul 30 20:18:55 CST 2023, time=2023-07-30, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=600522, encodeId=384d600522d2, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤免疫 经验分享：1月23日过年之前投一篇article，3月3日审稿回来大修。三个审稿人一个没意见，另外俩一共提了9个意见，都还比较到要害，可见审稿人水平很高。一个月时间修改后发回，5月初被接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=312, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ec85338815, createdName=ms6000001848255584, createdTime=Mon May 25 19:43:18 CST 2020, time=2020-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2098657, encodeId=a42d209865e47, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;Cancer 经验分享：杂志主要接收临床相关的文章，观点新颖，提出新的肿瘤治疗方案，并用详细严谨的临床数据作支撑。15年以后比较少接收基础类的文章，还是挺不错的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sat Nov 05 09:22:52 CST 2022, time=2022-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553812, encodeId=a27b5538126a, content=博士.结果怎么样?jfazj 2017-10-17 发表:: 研究方向:radiotherapy;; 接收率:约5% 审稿时间:约2个月 SCI(2016):12.589 SCI(2015):11.37 SCI(2014):12.583 mark一下.投稿42天.希望10月底能收到 decision letter! 希望有个好结果!jfazj 2017-10-17 11:09:00 发表: mark一下.投稿42天.希望10月底能收到 decision letter! 希望有个好结果!, beContent=jfazj 2017-10-17 发表:: 研究方向:radiotherapy;; 接收率:约5% 审稿时间:约2个月 SCI(2016):12.589 SCI(2015):11.37 SCI(2014):12.583 mark一下.投稿42天.希望10月底能收到 decision letter! 希望有个好结果!, objectType=tool_impact_factor, channel=null, level=null, likeNumber=418, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170224/IMG58AFD85BAD0444153.jpg, createdBy=25412017681, createdName=Dr. H, createdTime=Sat Mar 17 00:00:00 CST 2018, time=2018-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093753, encodeId=894b1093e5346, content=常见的SCI文章类型有哪些？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=176, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=)]

2023-07-30 ms2000000185262432 来自广西

投稿命中率:25.0
偏重的研究方向：甲状腺肿瘤
经验分享：Submission Technical Check Started：一周
Under consideration：一周
rejected

162 0

[GetPortalCommentsPageByObjectIdResponse(id=2244552, encodeId=6f3a224455268, content=没外审就review complete是啥意思，也不作出决定, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0f86442273, createdName=ms4000000681775086, createdTime=Mon Dec 23 20:55:52 CST 2024, time=2024-12-23, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=1079952, encodeId=92e010e995260, content=很快变成review complete 是不是秒拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEKtz8V7A0HhUFibPwRaIGuVmkOabRMZMFdRzw39RErlwqwxiciatOSOF6EKvqzCXFYU9BfOU8wA9KAWg/0, createdBy=32b61932414, createdName=OceanSL, createdTime=Tue Dec 14 14:58:43 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=564430, encodeId=5e72564430bc, content=Submission Technical Check Started状态持续了快半个月了，是不是放假了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=380, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26b81522186, createdName=jfazj, createdTime=Fri Dec 14 11:44:00 CST 2018, time=2018-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2155971, encodeId=de6721559e1b7, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：很好的期刊，只是这些年有点落寞了，不好中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/iaqwic5175nrsPthItiav2krgITEeMQ2icKV217mmNAw5IbUf9IZhxfJ4qIfOo59YMibg9n6KuicjX6wFCibesxO8bpOtCb4DsFbp41/0, createdBy=1a8e2047779, createdName=ms9508293866653270, createdTime=Mon Sep 04 08:27:39 CST 2023, time=2023-09-04, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2149454, encodeId=6c10214945484, content=偏重的研究方向：肿瘤 经验分享：投稿后，under consideration4周了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57818111868, createdName=ms6000001984003159, createdTime=Sun Jul 23 16:52:24 CST 2023, time=2023-07-23, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2150540, encodeId=ccec215054061, content=投稿命中率:25.0 偏重的研究方向：甲状腺肿瘤 经验分享：Submission Technical Check Started：一周 Under consideration：一周 rejected, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8336506161, createdName=ms2000000185262432, createdTime=Sun Jul 30 20:18:55 CST 2023, time=2023-07-30, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=600522, encodeId=384d600522d2, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤免疫 经验分享：1月23日过年之前投一篇article，3月3日审稿回来大修。三个审稿人一个没意见，另外俩一共提了9个意见，都还比较到要害，可见审稿人水平很高。一个月时间修改后发回，5月初被接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=312, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ec85338815, createdName=ms6000001848255584, createdTime=Mon May 25 19:43:18 CST 2020, time=2020-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2098657, encodeId=a42d209865e47, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;Cancer 经验分享：杂志主要接收临床相关的文章，观点新颖，提出新的肿瘤治疗方案，并用详细严谨的临床数据作支撑。15年以后比较少接收基础类的文章，还是挺不错的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sat Nov 05 09:22:52 CST 2022, time=2022-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553812, encodeId=a27b5538126a, content=博士.结果怎么样?jfazj 2017-10-17 发表:: 研究方向:radiotherapy;; 接收率:约5% 审稿时间:约2个月 SCI(2016):12.589 SCI(2015):11.37 SCI(2014):12.583 mark一下.投稿42天.希望10月底能收到 decision letter! 希望有个好结果!jfazj 2017-10-17 11:09:00 发表: mark一下.投稿42天.希望10月底能收到 decision letter! 希望有个好结果!, beContent=jfazj 2017-10-17 发表:: 研究方向:radiotherapy;; 接收率:约5% 审稿时间:约2个月 SCI(2016):12.589 SCI(2015):11.37 SCI(2014):12.583 mark一下.投稿42天.希望10月底能收到 decision letter! 希望有个好结果!, objectType=tool_impact_factor, channel=null, level=null, likeNumber=418, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170224/IMG58AFD85BAD0444153.jpg, createdBy=25412017681, createdName=Dr. H, createdTime=Sat Mar 17 00:00:00 CST 2018, time=2018-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093753, encodeId=894b1093e5346, content=常见的SCI文章类型有哪些？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=176, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=)]

2020-05-25 ms6000001848255584

审稿速度:2.0 | 投稿命中率:25.0
偏重的研究方向：肿瘤免疫
经验分享：1月23日过年之前投一篇article，3月3日审稿回来大修。三个审稿人一个没意见，另外俩一共提了9个意见，都还比较到要害，可见审稿人水平很高。一个月时间修改后发回，5月初被接收。

312 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2244552, encodeId=6f3a224455268, content=没外审就review complete是啥意思，也不作出决定, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0f86442273, createdName=ms4000000681775086, createdTime=Mon Dec 23 20:55:52 CST 2024, time=2024-12-23, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=1079952, encodeId=92e010e995260, content=很快变成review complete 是不是秒拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEKtz8V7A0HhUFibPwRaIGuVmkOabRMZMFdRzw39RErlwqwxiciatOSOF6EKvqzCXFYU9BfOU8wA9KAWg/0, createdBy=32b61932414, createdName=OceanSL, createdTime=Tue Dec 14 14:58:43 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=564430, encodeId=5e72564430bc, content=Submission Technical Check Started状态持续了快半个月了，是不是放假了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=380, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26b81522186, createdName=jfazj, createdTime=Fri Dec 14 11:44:00 CST 2018, time=2018-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2155971, encodeId=de6721559e1b7, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：很好的期刊，只是这些年有点落寞了，不好中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/iaqwic5175nrsPthItiav2krgITEeMQ2icKV217mmNAw5IbUf9IZhxfJ4qIfOo59YMibg9n6KuicjX6wFCibesxO8bpOtCb4DsFbp41/0, createdBy=1a8e2047779, createdName=ms9508293866653270, createdTime=Mon Sep 04 08:27:39 CST 2023, time=2023-09-04, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2149454, encodeId=6c10214945484, content=偏重的研究方向：肿瘤 经验分享：投稿后，under consideration4周了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57818111868, createdName=ms6000001984003159, createdTime=Sun Jul 23 16:52:24 CST 2023, time=2023-07-23, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2150540, encodeId=ccec215054061, content=投稿命中率:25.0 偏重的研究方向：甲状腺肿瘤 经验分享：Submission Technical Check Started：一周 Under consideration：一周 rejected, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8336506161, createdName=ms2000000185262432, createdTime=Sun Jul 30 20:18:55 CST 2023, time=2023-07-30, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=600522, encodeId=384d600522d2, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤免疫 经验分享：1月23日过年之前投一篇article，3月3日审稿回来大修。三个审稿人一个没意见，另外俩一共提了9个意见，都还比较到要害，可见审稿人水平很高。一个月时间修改后发回，5月初被接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=312, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ec85338815, createdName=ms6000001848255584, createdTime=Mon May 25 19:43:18 CST 2020, time=2020-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2098657, encodeId=a42d209865e47, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;Cancer 经验分享：杂志主要接收临床相关的文章，观点新颖，提出新的肿瘤治疗方案，并用详细严谨的临床数据作支撑。15年以后比较少接收基础类的文章，还是挺不错的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sat Nov 05 09:22:52 CST 2022, time=2022-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553812, encodeId=a27b5538126a, content=博士.结果怎么样?jfazj 2017-10-17 发表:: 研究方向:radiotherapy;; 接收率:约5% 审稿时间:约2个月 SCI(2016):12.589 SCI(2015):11.37 SCI(2014):12.583 mark一下.投稿42天.希望10月底能收到 decision letter! 希望有个好结果!jfazj 2017-10-17 11:09:00 发表: mark一下.投稿42天.希望10月底能收到 decision letter! 希望有个好结果!, beContent=jfazj 2017-10-17 发表:: 研究方向:radiotherapy;; 接收率:约5% 审稿时间:约2个月 SCI(2016):12.589 SCI(2015):11.37 SCI(2014):12.583 mark一下.投稿42天.希望10月底能收到 decision letter! 希望有个好结果!, objectType=tool_impact_factor, channel=null, level=null, likeNumber=418, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170224/IMG58AFD85BAD0444153.jpg, createdBy=25412017681, createdName=Dr. H, createdTime=Sat Mar 17 00:00:00 CST 2018, time=2018-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093753, encodeId=894b1093e5346, content=常见的SCI文章类型有哪些？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=176, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=)]

2022-11-05 slientwo

审稿速度:1.0 | 投稿命中率:50.0
偏重的研究方向：肿瘤;Cancer
经验分享：杂志主要接收临床相关的文章，观点新颖，提出新的肿瘤治疗方案，并用详细严谨的临床数据作支撑。15年以后比较少接收基础类的文章，还是挺不错的杂志。

121 0

[GetPortalCommentsPageByObjectIdResponse(id=2244552, encodeId=6f3a224455268, content=没外审就review complete是啥意思，也不作出决定, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0f86442273, createdName=ms4000000681775086, createdTime=Mon Dec 23 20:55:52 CST 2024, time=2024-12-23, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=1079952, encodeId=92e010e995260, content=很快变成review complete 是不是秒拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEKtz8V7A0HhUFibPwRaIGuVmkOabRMZMFdRzw39RErlwqwxiciatOSOF6EKvqzCXFYU9BfOU8wA9KAWg/0, createdBy=32b61932414, createdName=OceanSL, createdTime=Tue Dec 14 14:58:43 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=564430, encodeId=5e72564430bc, content=Submission Technical Check Started状态持续了快半个月了，是不是放假了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=380, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26b81522186, createdName=jfazj, createdTime=Fri Dec 14 11:44:00 CST 2018, time=2018-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2155971, encodeId=de6721559e1b7, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：很好的期刊，只是这些年有点落寞了，不好中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/iaqwic5175nrsPthItiav2krgITEeMQ2icKV217mmNAw5IbUf9IZhxfJ4qIfOo59YMibg9n6KuicjX6wFCibesxO8bpOtCb4DsFbp41/0, createdBy=1a8e2047779, createdName=ms9508293866653270, createdTime=Mon Sep 04 08:27:39 CST 2023, time=2023-09-04, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2149454, encodeId=6c10214945484, content=偏重的研究方向：肿瘤 经验分享：投稿后，under consideration4周了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57818111868, createdName=ms6000001984003159, createdTime=Sun Jul 23 16:52:24 CST 2023, time=2023-07-23, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2150540, encodeId=ccec215054061, content=投稿命中率:25.0 偏重的研究方向：甲状腺肿瘤 经验分享：Submission Technical Check Started：一周 Under consideration：一周 rejected, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8336506161, createdName=ms2000000185262432, createdTime=Sun Jul 30 20:18:55 CST 2023, time=2023-07-30, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=600522, encodeId=384d600522d2, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤免疫 经验分享：1月23日过年之前投一篇article，3月3日审稿回来大修。三个审稿人一个没意见，另外俩一共提了9个意见，都还比较到要害，可见审稿人水平很高。一个月时间修改后发回，5月初被接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=312, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ec85338815, createdName=ms6000001848255584, createdTime=Mon May 25 19:43:18 CST 2020, time=2020-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2098657, encodeId=a42d209865e47, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;Cancer 经验分享：杂志主要接收临床相关的文章，观点新颖，提出新的肿瘤治疗方案，并用详细严谨的临床数据作支撑。15年以后比较少接收基础类的文章，还是挺不错的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sat Nov 05 09:22:52 CST 2022, time=2022-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553812, encodeId=a27b5538126a, content=博士.结果怎么样?jfazj 2017-10-17 发表:: 研究方向:radiotherapy;; 接收率:约5% 审稿时间:约2个月 SCI(2016):12.589 SCI(2015):11.37 SCI(2014):12.583 mark一下.投稿42天.希望10月底能收到 decision letter! 希望有个好结果!jfazj 2017-10-17 11:09:00 发表: mark一下.投稿42天.希望10月底能收到 decision letter! 希望有个好结果!, beContent=jfazj 2017-10-17 发表:: 研究方向:radiotherapy;; 接收率:约5% 审稿时间:约2个月 SCI(2016):12.589 SCI(2015):11.37 SCI(2014):12.583 mark一下.投稿42天.希望10月底能收到 decision letter! 希望有个好结果!, objectType=tool_impact_factor, channel=null, level=null, likeNumber=418, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170224/IMG58AFD85BAD0444153.jpg, createdBy=25412017681, createdName=Dr. H, createdTime=Sat Mar 17 00:00:00 CST 2018, time=2018-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093753, encodeId=894b1093e5346, content=常见的SCI文章类型有哪些？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=176, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=)]

2018-03-17 Dr. H

博士.结果怎么样?jfazj 2017-10-17 发表::
研究方向:radiotherapy;; 接收率:约5% 审稿时间:约2个月 SCI(2016):12.589 SCI(2015):11.37 SCI(2014):12.583 mark一下.投稿42天.希望10月底能收到 decision letter! 希望有个好结果!jfazj 2017-10-17 11:09:00 发表:
mark一下.投稿42天.希望10月底能收到 decision letter! 希望有个好结果!

jfazj 2017-10-17 发表:: 研究方向:radiotherapy;; 接收率:约5% 审稿时间:约2个月 SCI(2016):12.589 SCI(2015):11.37 SCI(2014):12.583 mark一下.投稿42天.希望10月底能收到 decision letter! 希望有个好结果!

418 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2244552, encodeId=6f3a224455268, content=没外审就review complete是啥意思，也不作出决定, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=8, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0f86442273, createdName=ms4000000681775086, createdTime=Mon Dec 23 20:55:52 CST 2024, time=2024-12-23, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=1079952, encodeId=92e010e995260, content=很快变成review complete 是不是秒拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEKtz8V7A0HhUFibPwRaIGuVmkOabRMZMFdRzw39RErlwqwxiciatOSOF6EKvqzCXFYU9BfOU8wA9KAWg/0, createdBy=32b61932414, createdName=OceanSL, createdTime=Tue Dec 14 14:58:43 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=564430, encodeId=5e72564430bc, content=Submission Technical Check Started状态持续了快半个月了，是不是放假了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=380, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26b81522186, createdName=jfazj, createdTime=Fri Dec 14 11:44:00 CST 2018, time=2018-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2155971, encodeId=de6721559e1b7, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：很好的期刊，只是这些年有点落寞了，不好中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/iaqwic5175nrsPthItiav2krgITEeMQ2icKV217mmNAw5IbUf9IZhxfJ4qIfOo59YMibg9n6KuicjX6wFCibesxO8bpOtCb4DsFbp41/0, createdBy=1a8e2047779, createdName=ms9508293866653270, createdTime=Mon Sep 04 08:27:39 CST 2023, time=2023-09-04, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2149454, encodeId=6c10214945484, content=偏重的研究方向：肿瘤 经验分享：投稿后，under consideration4周了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57818111868, createdName=ms6000001984003159, createdTime=Sun Jul 23 16:52:24 CST 2023, time=2023-07-23, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2150540, encodeId=ccec215054061, content=投稿命中率:25.0 偏重的研究方向：甲状腺肿瘤 经验分享：Submission Technical Check Started：一周 Under consideration：一周 rejected, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8336506161, createdName=ms2000000185262432, createdTime=Sun Jul 30 20:18:55 CST 2023, time=2023-07-30, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=600522, encodeId=384d600522d2, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤免疫 经验分享：1月23日过年之前投一篇article，3月3日审稿回来大修。三个审稿人一个没意见，另外俩一共提了9个意见，都还比较到要害，可见审稿人水平很高。一个月时间修改后发回，5月初被接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=312, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ec85338815, createdName=ms6000001848255584, createdTime=Mon May 25 19:43:18 CST 2020, time=2020-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2098657, encodeId=a42d209865e47, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;Cancer 经验分享：杂志主要接收临床相关的文章，观点新颖，提出新的肿瘤治疗方案，并用详细严谨的临床数据作支撑。15年以后比较少接收基础类的文章，还是挺不错的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Sat Nov 05 09:22:52 CST 2022, time=2022-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553812, encodeId=a27b5538126a, content=博士.结果怎么样?jfazj 2017-10-17 发表:: 研究方向:radiotherapy;; 接收率:约5% 审稿时间:约2个月 SCI(2016):12.589 SCI(2015):11.37 SCI(2014):12.583 mark一下.投稿42天.希望10月底能收到 decision letter! 希望有个好结果!jfazj 2017-10-17 11:09:00 发表: mark一下.投稿42天.希望10月底能收到 decision letter! 希望有个好结果!, beContent=jfazj 2017-10-17 发表:: 研究方向:radiotherapy;; 接收率:约5% 审稿时间:约2个月 SCI(2016):12.589 SCI(2015):11.37 SCI(2014):12.583 mark一下.投稿42天.希望10月底能收到 decision letter! 希望有个好结果!, objectType=tool_impact_factor, channel=null, level=null, likeNumber=418, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170224/IMG58AFD85BAD0444153.jpg, createdBy=25412017681, createdName=Dr. H, createdTime=Sat Mar 17 00:00:00 CST 2018, time=2018-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093753, encodeId=894b1093e5346, content=常见的SCI文章类型有哪些？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=176, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:49 CST 2021, time=2021-12-29, status=1, ipAttribution=)]

2021-12-29 ms6000000264964247

常见的SCI文章类型有哪些？

176 1

展开1条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务